Top

Published in:

01-06-2020 | Metastasis | Neuroendocrine Cancers (JR Strosberg, Section Editor)

Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms

Authors: Valentina Andreasi, MD, Francesca Muffatti, MD, Giovanni Guarneri, MD, Massimo Falconi, MD, Stefano Partelli, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 6/2020

Opinion statement

Pancreatic neuroendocrine neoplasms (PanNENs) are increasingly recognized entities, whose incidence has dramatically grown during the last two decades. Surgery plays a pivotal role in their management as it represents the only chance of cure. Since PanNENs display a wide range of aggressiveness, their surgical management needs to be tailored on tumor’s and patient’s characteristics. Currently, there are several open questions and burning issues in the field of PanNEN, such as the management of asymptomatic nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET) ≤ 2 cm. An active surveillance of these small lesions has been demonstrated to be safe although the available evidences are only based on retrospective studies. On the other hand, formal pancreatic resection associated with lymphadenectomy represents the gold standard for patients with localized NF-PanNEN > 2 cm or NF-PanNEN ≤ 2 cm in the presence of symptoms, dilation of the main pancreatic duct or suspicion of nodal metastases. Surgery plays also an important role in the setting of metastatic disease. In particular, surgery is generally recommended in the presence of low-grade, resectable, metastatic disease, but several series have reported also a survival benefit of palliative primary tumor resection in patients with unresectable liver metastases. The role of surgery in PanNEN G3 is still controversial. Indeed, surgery is associated with an improved survival in patients with well-differentiated PanNET G3, whereas there is almost no survival benefit in case of poorly differentiated lesions.

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef

Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20(9):2815–21.PubMedCrossRef

Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008. https://doi.org/10.1002/bjs.6051.PubMedCrossRef

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016. https://doi.org/10.1159/000443171.PubMedCrossRef

Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33.PubMedCrossRefPubMedCentral

Partelli S, Giannone F, Schiavo Lena M, Muffatti F, Andreasi V, Crippa S, et al. Is the real prevalence of pancreatic neuroendocrine tumors underestimated? A retrospective study on a large series of pancreatic specimens. Neuroendocrinology. 2019. https://doi.org/10.1159/000499606.PubMedCrossRef

Ricci C, Casadei R, Taffurelli G, Pacilio CA, Campana D, Ambrosini V, et al. Sporadic small (</=20 mm) nonfunctioning pancreatic neuroendocrine neoplasm: is the risk of malignancy negligible when adopting a more conservative strategy? A systematic review and meta-analysis. Ann Surg Oncol. 2017 Sep;24(9):2603–10.PubMedCrossRef

Partelli S, Cirocchi R, Crippa S, Cardinali L, Fendrich V, Bartsch DK, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2017 Jan;104(1):34–41.PubMedCrossRef

10.

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Cancer Netw. 2018 DOI: https://doi.org/10.6004/jnccn.2018.0056 PubMedCrossRef

11.

Barenboim A, Lahat G, Nachmany I, Nakache R, Goykhman Y, Geva R, et al. Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg. 2019:1–9. https://doi.org/10.1007/s11605-019-04285-y.

12.

• Partelli S, Mazza M, Andreasi V, Muffatti F, Crippa S, Tamburrino D, et al. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: limitations to apply guidelines into real life. Surg (United States). 2019. https://doi.org/10.1016/j.surg.2019.04.003 Series showing the real-life management of patients with asymptomatic NF-PanNET ≤2 cm, highlighting the challenging situations in which guidelines are not applied.PubMedCrossRef

13.

Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, et al. Surgery versus surveillance for well-differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11-year analysis of the National Cancer Database. Oncologist. 2019. https://doi.org/10.1634/theoncologist.2019-0466.

14.

•• Powers BD, Rothermel LD, Fleming JB, Strosberg JR, Anaya DA. A survival analysis of patients with localized, asymptomatic pancreatic neuroendocrine tumors: no surgical survival benefit when examining appropriately selected outcomes. J Gastrointest Surg. 2019. https://doi.org/10.1007/s11605-019-04433-4 Series investigating the long-term outcomes of patients with asymptomatic NF-PanNET ≤2 cm managed with surgery or active surveillance.

15.

Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, et al. Implementation of current ENETS guidelines for surgery of small (≤2 cm) pancreatic neuroendocrine neoplasms in the German surgical community: an analysis of the prospective DGAV StuDoQ|pancreas registry. World J Surg. 2019;43:175–82. https://doi.org/10.1007/s00268-018-4751-2.CrossRefPubMed

16.

Dong D-H, Zhang X-F, Poultsides G, Rocha F, Weber S, Fields R, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors </=2 cm after curative resection: a multi-institutional study of 392 cases. J Surg Oncol. 2019 Dec;120(7):1071–9.PubMedCrossRef

17.

Partelli S, Muffatti F, Rancoita PMV, Andreasi V, Balzano G, Crippa S, et al. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. Dig Liver Dis. 2019 May;51(5):735–40.PubMedCrossRef

18.

Lopez-Aguiar AG, Ethun CG, Zaidi MY, Rocha FG, Poultsides GA, Dillhoff M, et al. The conundrum of < 2-cm pancreatic neuroendocrine tumors: a preoperative risk score to predict lymph node metastases and guide surgical management. Surgery. 2019 Jul;166(1):15–21.PubMedCrossRef

19.

Lloyd RV, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.

20.

Partelli S, Tamburrino D, Cherif R, Muffatti F, Moggia E, Gaujoux S, et al. Risk and predictors of postoperative morbidity and mortality after pancreaticoduodenectomy for pancreatic neuroendocrine neoplasms: a comparative study with pancreatic ductal adenocarcinoma. Pancreas. 2019;48(4):504–9.PubMedCrossRef

21.

Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg. 2018. https://doi.org/10.1097/sla.0000000000003022.PubMedCrossRef

22.

Cives M, Partelli S, Palmirotta R, Lovero D, Mandriani B, Quaresmini D, et al. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2019;9(1):18614.PubMedPubMedCentralCrossRef

23.

Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. 2013. https://doi.org/10.1001/jamasurg.2013.3376.PubMedCrossRef

24.

Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259(2):197–203.PubMedCrossRef

25.

Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2014;19:152–60. https://doi.org/10.1007/s11605-014-2624-z.CrossRefPubMed

26.

Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, et al. A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003461.PubMedCrossRef

27.

Genc CG, Jilesen AP, Partelli S, Falconi M, Muffatti F, van Kemenade FJ, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018 Jun;267(6):1148–54.PubMedCrossRef

28.

Genç CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C, et al. Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol. 2018;25:2467–74. https://doi.org/10.1245/s10434-018-6518-2.CrossRefPubMedPubMedCentral

29.

•• Partelli S, Javed AA, Andreasi V, He J, Muffatti F, Weiss MJ, et al. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. Eur J Surg Oncol. 2018;44(6). https://doi.org/10.1016/j.ejso.2018.03.005 This series investigates the prognostic role of the number of positive lymph nodes in patients submitted to pancreaticoduodenectomy for NF-PanNEN and it proposes a minimum number of lymph nodes to be resected in order to guarantee an adequate nodal staging.PubMedCrossRef

30.

Capretti G, Nappo G, Smiroldo V, Cereda M, Branciforte B, Spaggiari P, et al. The number of metastatic lymph nodes is a useful predictive factor for recurrence after surgery for nonmetastatic nonfunctional neuroendocrine neoplasm of the pancreas. Gastroenterol Res Pract. 2019. https://doi.org/10.1155/2019/6856329.CrossRef

31.

Zhang X-F, Xue F, Dong D-H, Lopez-Aguiar AG, Poultsides G, Makris E, et al. New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and National Data Analysis. Ann Surg. 2019 Jul. https://doi.org/10.1097/SLA.0000000000003478.

32.

Wu L, Sahara K, Tsilimigras DI, Maithel SK, Poultsides GA, Rocha FG, et al. Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: a multi-institutional analysis. J Surg Oncol. 2019 Dec;120(7):1080–6.PubMedCrossRef

33.

Mao R, Zhao H, Li K, Luo S, Turner M, Cai J-Q, et al. Outcomes of lymph node dissection for non-metastatic pancreatic neuroendocrine tumors: a propensity score-weighted analysis of the National Cancer Database. Ann Surg Oncol. 2019 Sep;26(9):2722–9.PubMedCrossRefPubMedCentral

34.

Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, et al. Evaluation of the site and frequency of lymph node metastasis with non-functioning pancreatic neuroendocrine tumor. Eur Surg Res. 2019:1–10.

35.

•• Lopez-Aguiar AG, Zaidi MY, Beal EW, Dillhoff M, JGD C, Poultsides GA, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: an eight-institution study of 695 patients from the US neuroendocrine tumor study group. Ann Surg Oncol. 2019;26(8):2517–24 This series investigates the prognostic role of the number of positive lymph nodes in patients submitted to distal pancreatectomy for NF-PanNEN and it proposes a minimum number of lymph nodes to be resected in order to guarantee an adequate nodal staging.PubMedCrossRef

36.

Sahara K, Tsilimigras DI, Mehta R, Moro A, Paredes AZ, Lopez-Aguiar AG, et al. Trends in the number of lymph nodes evaluated among patients with pancreatic neuroendocrine tumors in the United States: a multi-institutional and National Database Analysis. Ann Surg Oncol. 2019:1–10. https://doi.org/10.1245/s10434-019-08120-1.PubMedCrossRef

37.

•• Partelli S, Bertani E, Bartolomei M, Perali C, Muffatti F, Grana CM, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018. https://doi.org/10.1016/j.surg.2017.11.007 Series investigating the role of neoadjuvant peptide receptor radionuclide therapy for those patients with resectable or potentially resectable PanNEN displaying features at high risk for recurrence.PubMedCrossRef

38.

Zhang X-F, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, et al. Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: an analysis from the U.S. neuroendocrine tumor study group. J Surg Oncol. 2019;120(2):231–40.PubMed

39.

Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105(3):255–65.PubMedCrossRef

40.

Xourafas D, Tavakkoli A, Clancy TE, Ashley SW. Distal pancreatic resection for neuroendocrine tumors: is laparoscopic really better than open? J Gastrointest Surg. 2015. https://doi.org/10.1007/s11605-015-2788-1.PubMedPubMedCentralCrossRef

41.

Edwin B, Sahakyan MA, Abu Hilal M, Besselink MG, Braga M, Fabre JM, et al. Laparoscopic surgery for pancreatic neoplasms: the European association for endoscopic surgery clinical consensus conference. Surg Endosc. 2017;31:2023–41. https://doi.org/10.1007/s00464-017-5414-3.CrossRefPubMed

42.

Casadei R, Ricci C, D’Ambra M, Marrano N, Alagna V, Rega D, et al. Laparoscopic versus open distal pancreatectomy in pancreatic tumours: a case-control study. Updat Surg. 2010;62:171–4. https://doi.org/10.1007/s13304-010-0027-6.CrossRef

43.

Tamburrino D, Partelli S, Renzi C, Crippa S, Muffatti F, Perali C, et al. Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs). Expert Rev Gastroenterol Hepatol. 2017 Jan;11(1):65–73.PubMedCrossRef

44.

Drymousis P, Raptis DA, Spalding D, Fernandez-Cruz L, Menon D, Breitenstein S, et al. Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis. HPB. 2014. https://doi.org/10.1111/hpb.12162.PubMedCrossRef

45.

• Partelli S, Andreasi V, PMV R, Perez-Sanchez E, Muffatti F, Balzano G, et al. Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. Surg Endosc. 2020. https://doi.org/10.1007/s00464-020-07375-0 Series comparing short-term and long-term outcomes in a very selected population of patients submitted to open or laparoscopic DP for NF-PanNEN, using a propensity score weighting to minimize selection bias.

46.

Alfieri S, Butturini G, Boggi U, Pietrabissa A, Morelli L, Vistoli F, et al. Short-term and long-term outcomes after robot-assisted versus laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors (pNETs): a multicenter comparative study. Langenbeck's Arch Surg. 2019 Jun;404(4):459–68.CrossRef

47.

Guerrini GP, Lauretta A, Belluco C, Olivieri M, Forlin M, Basso S, et al. Robotic versus laparoscopic distal pancreatectomy: an up-to-date meta-analysis. BMC Surg. 2017 Nov;17(1):105.PubMedPubMedCentralCrossRef

48.

Zureikat AH, Borrebach J, Pitt HA, Mcgill D, Hogg ME, Thompson V, et al. Minimally invasive hepatopancreatobiliary surgery in North America: an ACS-NSQIP analysis of predictors of conversion for laparoscopic and robotic pancreatectomy and hepatectomy. HPB (Oxford). 2017 Jul;19(7):595–602.CrossRef

49.

Nassour I, Wang SC, Porembka MR, Augustine MM, Yopp AC, Mansour JC, et al. Conversion of minimally invasive distal pancreatectomy: predictors and outcomes. Ann Surg Oncol. 2017;24:3725–31. https://doi.org/10.1245/s10434-017-6062-5.CrossRefPubMed

50.

Andreasi V, Partelli S, Capurso G, Muffatti F, Balzano G, Crippa S, et al. Long-term pancreatic functional impairment after surgery for neuroendocrine neoplasms. J Clin Med. 2019;8(10). https://doi.org/10.3390/jcm8101611.PubMedCentralCrossRef

51.

King J, Kazanjian K, Matsumoto J, Reber HA, Yeh MW, Hines OJ, et al. Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg. 2008. https://doi.org/10.1007/s11605-008-0560-5.PubMedCrossRef

52.

Lim PW, Dinh KH, Sullivan M, Wassef WY, Zivny J, Whalen GF, et al. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB. 2016. https://doi.org/10.1016/j.hpb.2015.11.003.PubMedPubMedCentralCrossRef

53.

Huttner FJ, Koessler-Ebs J, Hackert T, Ulrich A, Buchler MW, Diener MK. Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms. Br J Surg. 2015 Aug;102(9):1026–36.PubMedCrossRef

54.

Belfiori G, Wiese D, Partelli S, Wachter S, Maurer E, Crippa S, et al. Minimally invasive versus open treatment for benign sporadic insulinoma comparison of short-term and long-term outcomes. World J Surg. 2018 Oct;42(10):3223–30.PubMedCrossRef

55.

Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011 Jul;150(1):75–82.PubMedCrossRef

56.

• Paiella S, De Pastena M, Faustini F, Landoni L, Pollini T, Bonamini D, et al. Central pancreatectomy for benign or low-grade malignant pancreatic lesions - a single-center retrospective analysis of 116 cases. Eur J Surg Oncol. 2019. https://doi.org/10.1016/j.ejso.2018.11.021 Series reporting the outcomes of central pancreatectomy in patients with benign or low-grade malignant leasions, of whom 89% were PanNEN.PubMedCrossRef

57.

Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan;15(1):e8–21.PubMedCrossRef

58.

Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.CrossRefPubMed

59.

Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, et al. Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology. 2015;102(1–2):68–76.PubMedCrossRef

60.

Bertani E, Fazio N, Radice D, Zardini C, Spinoglio G, Chiappa A, et al. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. Eur J Surg Oncol. 2017 Feb;43(2):372–9.PubMedCrossRef

61.

Citterio D, Pusceddu S, Facciorusso A, Coppa J, Milione M, Buzzoni R, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol. 2017 Feb;43(2):380–7.PubMedCrossRef

62.

• Partelli S, Cirocchi R, PMV R, Muffatti F, Andreasi V, Crippa S, et al. A systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB. 2018;20(3). https://doi.org/10.1016/j.hpb.2017.10.014 Overview of the results of palliative primary resection for PanNEN with unresectable liver metastases.PubMedCrossRef

63.

Almond LM, Hodson J, Ford SJ, Gourevitch D, Roberts KJ, Shah T, et al. Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: a systematic review and meta-analysis. Eur J Surg Oncol. 2017 Oct;43(10):1808–15.PubMedCrossRef

64.

Ye H, Xu HL, Shen Q, Zheng Q, Chen P. Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors. J Surg Res. 2019 Nov;243:578–87.PubMedCrossRef

65.

Zhang J, Peng C-S, Tian Y-H. Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: to do or not to do? Clin Interv Aging. 2019;14:1419–32.PubMedPubMedCentralCrossRef

66.

Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, Hertl M, et al. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2019 Mar;165(3):644–51.PubMedCrossRef

67.

Kaemmerer D, Twrznik M, Kulkarni HR, Hörsch D, Sehner S, Baum RP, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms. Ann Surg. 2019;15:5867–70.

68.

Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1–G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23:981–9. https://doi.org/10.1245/s10434-016-5550-3.CrossRefPubMed

69.

Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010 Dec;17(12):3129–36.PubMedCrossRef

70.

Ejaz A, Reames BN, Maithel S, Poultsides GA, Bauer TW, Fields RC, et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford). 2018 Mar;20(3):277–84.CrossRef

71.

Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003 Jul;197(1):29–37.PubMedCrossRef

72.

McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108(6):1091–6.PubMed

73.

Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):643–5.CrossRef

74.

Maxwell JE, Sherman SK, O’Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery. 2016;159(1):320–33.PubMedCrossRef

75.

• Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218–25 Series investigating oncological outcomes based on the percent of liver debulking.PubMedCrossRef

76.

•• Al-Toubah T, Partelli S, Cives M, Andreasi V, Silvestris F, Falconi M, et al. Local treatment for focal progression in metastatic neuroendocrine tumors. Endocr Relat Cancer. 2018. https://doi.org/10.1530/ERC-18-0462 Series investigating the role of local treatments in focal disease progression, highlighting that this management enabled patients to remain on their existing systemic treatment.PubMedCrossRef

77.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. 2017;105(3):281–94.PubMedCrossRef

78.

Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug;39(6):799–800.PubMedPubMedCentralCrossRef

79.

Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters. Surgery. 2016 Mar;159(3):862–71.PubMedCrossRef

80.

Haugvik S-P, Janson ET, Osterlund P, Langer SW, Falk RS, Labori KJ, et al. Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a Nordic multicenter comparative study. Ann Surg Oncol. 2016 May;23(5):1721–8.PubMedCrossRef

81.

• Merola E, Rinke A, Partelli S, Gress TM, Andreasi V, Kollár A, et al. Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms? Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-08049-5 Series investigating the role of radical surgery in localized GEP-NEN G3.PubMedCrossRef

82.

•• Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, et al. Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07252-8 Series investigating the role of surgery in PanNEN G3, distinguishing between PanNET-G3 and PanNEC-G3, with and without distant metastases.PubMedCrossRef

83.

Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwaarde RS, de Herder WW, Dreijerink KMA, et al. Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 study group. J Clin Endocrinol Metab. 2017 Oct;102(10):3795–805.PubMedCrossRef

84.

Triponez F, Goudet P, Dosseh D, Cougard P, Bauters C, Murat A, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006 May;30(5):654.PubMedCrossRef

85.

Partelli S, Tamburrino D, Lopez C, Albers M, Milanetto AC, Pasquali C, et al. Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms </=2 cm in MEN1 patients. Neuroendocrinology. 2016;103(6):779–86.PubMedCrossRef

86.

Nell S, Verkooijen HM, Pieterman CRC, de Herder WW, Hermus AR, Dekkers OM, et al. Management of MEN1 related nonfunctioning pancreatic NETs: a shifting paradigm: results from the DutchMEN1 study group. Ann Surg. 2018 Jun;267(6):1155–60.PubMedCrossRef

87.

•• Triponez F, Sadowski SM, Pattou F, Cardot-Bauters C, Mirallie E, Le Bras M, et al. Long-term follow-up of MEN1 patients who do not have initial surgery for small </=2 cm nonfunctioning pancreatic neuroendocrine tumorS, an AFCE and GTE study: Association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines. Ann Surg. 2018;268(1):158–64 Series reporting the long-term outcomes of 46 patients with MEN1-associated NF-PanNEN ≤ 2 cm followed up for almost 11 years.PubMedCrossRef

Title: Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms
Authors: Valentina Andreasi, MD
Francesca Muffatti, MD
Giovanni Guarneri, MD
Massimo Falconi, MD
Stefano Partelli, MD, PhD
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Metastasis
Lymphadenectomy
Neuroendocrine Tumor
Published in: Current Treatment Options in Oncology / Issue 6/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-020-00736-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 6/2020

The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma

Current Treatment of Melanoma Brain Metastasis

PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions

Hereditary Syndromes in Neuroendocrine Tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer